Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F11 | P03951 | 17/20 | 0.34 |
| ▸ | KLKB1 | P03952 | 15/20 | 0.34 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.32 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | GRM7 | Q14831 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24987076 | 0.90 | F11 (0.33) | F11KLKB1NOTUMKCNH2CYP3A4 | |
| SCHEMBL16972351 | 0.88 | F11 (0.41) | F11KLKB1CYP3A4 | |
| SCHEMBL16971407 | 0.85 | F11 (0.35) | F11KLKB1NOTUMKCNH2CYP3A4 | |
| SCHEMBL18316524 | 0.85 | F11 (0.37) | F11KLKB1NOTUMCYP3A4 | |
| SCHEMBL16971384 | 0.85 | NOTUM (0.38) | F11KLKB1NOTUMKCNH2CYP3A4 | |
| SCHEMBL16971663 | 0.83 | NOTUM (0.40) | F11KLKB1NOTUMKCNH2CYP3A4 | |
| SCHEMBL18710672 | 0.83 | NR1I2 (0.39) | F11KLKB1NOTUMKCNH2CYP3A4 | |
| SCHEMBL16974699 | 0.83 | F11 (0.36) | F11KLKB1NOTUMKCNH2CYP3A4 | |
| SCHEMBL16971318 | 0.83 | F11 (0.35) | F11KLKB1CYP3A4 | |
| SCHEMBL30271794 | 0.83 | F11 (0.35) | F11KLKB1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230151010-A1 | CRYSTALLINE FORMS OF (9R, 135S)-13- {4-[5-CHLORO-2-(4-CHLORO-1H,2,3- TRIAZOL- 1 -YL)PHENYL] -6-OXO- 1,6-DIHYDROPYRIMIDIN- 1-YL}-3-(DIFLUOROMETHYL)-9-METHYL-3,4,7,15- TETRAAZATRICYCLO [ 12.3.1.0 2·6] OCTADECA- 1(18), 2(6), 4, 14, 16-PENTAEN-8-ONE | JANSSEN PHARMACEUTICA NV (BE) | 2023-05-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230151010-A1 | CRYSTALLINE FORMS OF (9R, 135S)-13- {4-[5-CHLORO-2-(4-CHLORO-1H,2,3- TRIAZOL- 1 -YL)PHENYL] -6-OXO- 1,6-DIHYDROPYRIMIDIN- 1-YL}-3-(DIFLUOROMETHYL)-9-METHYL-3,4,7,15- TETRAAZATRICYCLO [ 12.3.1.0 2·6] OCTADECA- 1(18), 2(6), 4, 14, 16-PENTAEN-8-ONE | CASP9, TMEM14C, CCT8 | F11 244/4885KLKB1 2903/4885NOTUM 2278/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.